The strategic alternatives process is open-ended with no timeline. Watch for any definitive agreement, asset sale, or dissolution plan. The cash runway of $94.8M provides some time but the company has no ongoing clinical programs and minimal revenue.
Drugs in focus
CRBU drug pipeline →CB-011
▼ Bearish Named in this 8-K- Impact
- Phase
- Phase 1 (discontinued)
- Time to market
- Not applicable. CB-011 development has been discontinued and the program terminated (Oct 2026).
- Next catalyst
- None dated
What to watchCB-011 development has been discontinued. The next event is the ASH 2026 presentation (Dec 12-15), but it is a look-back on a terminated program. The real stock-moving catalyst is the strategic alternatives process (potential sale/merger of Caribou), which has no announced timeline. Watch for any acquisition or asset-sale announcement from the company's exploration process.
How the stock moved after the report
BEARISH VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 6 $0.4487entry
- T+1 · 8d ago −6.44%α −8.81% · $0.4198
- T+5 · 4d ago −19.34%α −21.94% · $0.3619
- T+6 · todayOpen
- T+20 · in 20d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Caribou Biosciences reported Q3 2026 revenue of $1.6M (below $2.2M a year ago) and a GAAP net loss of $26.6M ($0.25 per share). The filing confirms the October 6 restructuring that discontinues both clinical programs (vispa-cel and CB-011) and launches a strategic alternatives process that may include dissolution and liquidation. The company has $94.8M in cash, down from $142.8M at year-end 2025.
Key Financial Metrics
Key Facts
- Q3 2026 licensing revenue $1.6M vs $2.2M a year ago
- GAAP net loss $26.6M ($0.25 per share) vs $27.5M ($0.30) a year ago
- Cash and marketable securities $94.8M as of Sep 30, 2026, down from $142.8M at Dec 31, 2025
- Board approved restructuring on Oct 6, 2026, discontinuing vispa-cel and CB-011 clinical trials
- Company is exploring strategic alternatives including merger, acquisition, business combination, or dissolution and liquidation
- Impairment charges of $12.15M and impairment of equity investment of $9.158M recorded in Q3 2026
- Market cap $49M with normal daily move of 12.6%
Financial Impact
Cash burn of ~$48M in nine months; $94.8M remaining; restructuring eliminates R&D spend on two clinical programs
Risk Factors
- No timeline for strategic alternatives process; outcome uncertain
- Potential dissolution and liquidation with uncertain recovery for equity holders
- No ongoing clinical programs; revenue from licensing is minimal and declining
- Impairment charges of $21.3M in Q3 2026 reflect asset write-downs
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001619856-26-000060 |
| Document: crbu-20261105.htm | 0001619856-26-000060 |
| Document: 0001619856-26-000060-index-headers.html | 0001619856-26-000060 |
| Document: 0001619856-26-000060-index.html | 0001619856-26-000060 |
| Document: 0001619856-26-000060.txt | 0001619856-26-000060 |
| 8-K Data (Synthetic) | 0001619856-26-000060 |
Track record
13 reports on CRBU
3 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +28.02% at T+20 after the Oct 6, 2026 report. 3 of 3 went positive at some point.
Filters
- Nov 5, 202611d ago 8-K Bearish 7/10 Viewing Entry $0.4487 Now $0.3530 +21.33% settles Dec 7
- Oct 6, 20265w ago 8-K Bearish 7/10 Entry $0.6174 to $0.4444 Now $0.3530 +42.82% ▲ +28.02% +26.68% vs SPY
- Sep 22, 20267w ago Institutional Cluster Mixed 3/10 Entry $1.34 to $0.5190 Now $0.3530 −73.66% ▼ −61.27% −60.71% vs SPY
- Jun 11, 202622w ago 8-K Bullish 6/10 Entry $1.66 to $1.94 Now $0.3530 −78.73% ▲ +16.87% +14.98% vs SPY
- Jun 11, 202622w ago Press Release Bullish 7/10 Entry $1.66 to $1.94 Now $0.3530 −78.73% ▲ +16.87% +14.98% vs SPY
- Jun 5, 202623w ago DEFA14A Neutral 2/10 Entry $1.84 to $1.83 Now $0.3530 −80.82% ▼ −0.54% −2.17% vs SPY
- Apr 24, 202629w ago DEFA14A Neutral 3/10 Entry $2.13 to $2.16 Now $0.3530 −83.43% ▲ +1.41% −3.55% vs SPY
- Mar 5, 202636w ago 8-K Mixed 5/10 Entry $1.82 to $1.95 Now $0.3530 −80.60% ▲ +7.14% +9.19% vs SPY
- Mar 5, 202636w ago Press Release Mixed 6/10 Entry $1.82 to $1.95 Now $0.3530 −80.60% ▲ +7.14% +9.19% vs SPY
- Feb 28, 202637w ago Institutional Cluster Neutral 5/10 Entry $1.84 to $1.72 Now $0.3530 −80.82% ▼ −6.52% +1.42% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers